Prescription Drugs · Oncology Therapeutics
Bristol Myers Squibb revenue, results and funding
Bristol Myers Squibb filed revenue of $48.2B for 2025.
Data updated Nov 21, 2026 · Back to the company report
$48.2BRevenue, 2025
$7.1BNet income, 2025
30,000Employees, 2019
BMYNew York Stock Exchange
Results by year
| Year | Revenue | Net income | Total assets | Employees | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_DIVIDENDS | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $48.2B | $7.1B | $90B | – | $3.3B | $2.3B | $5B | $0 | $1.3B | $553M | $10B | $10.2B | $42.9B | $3.9B |
| 2024 | $48.3B | −$8.9B | $92.6B | – | $3.9B | $554M | $4.9B | $0 | $1.2B | $507M | $11.2B | $10.3B | $47.6B | $21.8B |
| 2023 | $45B | $8B | $95.2B | – | $4.3B | $400M | $4.7B | $5.2B | $1.2B | $518M | $9.3B | $11.5B | $36.7B | $1.2B |
| 2022 | $46.2B | $6.3B | $96.8B | – | $5.4B | $1.4B | $4.6B | $8B | $1.1B | $457M | $9.5B | $9.1B | $35.1B | $4.3B |
| 2021 | $46.4B | $7B | $109.3B | – | $3.5B | $1.1B | $4.4B | $6.3B | $973M | $583M | $10.2B | $14B | $39.6B | $1.6B |
| 2020 | $42.5B | −$9B | $118.5B | – | $3.4B | $2.1B | $4.1B | $1.5B | $753M | $779M | $10B | $14.5B | $48.3B | $13.1B |
| 2019 | $26.1B | $3.4B | $128.1B | 30,000 | $1.5B | $1.5B | $2.7B | $7.3B | $836M | $441M | $6.1B | $19.9B | $43.4B | $24.8B |
| 2018 | $22.6B | $4.9B | $55.2B | – | $747M | $1B | $2.6B | $320M | $951M | $221M | $6.3B | $28.4B | $5.6B | $2.4B |
| 2017 | $20.8B | $1B | $32.6B | – | $546M | $4.2B | $2.6B | $2.5B | $1.1B | $199M | $6.5B | $5B | $7B | $726M |
| 2016 | $19.4B | $4.5B | $33.4B | – | $2B | $1.4B | $2.5B | $231M | $1.2B | $205M | $5B | $3.5B | $5.7B | $359M |
| 2015 | $16.6B | $1.6B | $32.8B | – | $577M | $446M | $2.5B | – | $820M | $235M | $5.9B | $2.4B | $6.6B | $1.1B |
| 2014 | $15.9B | $2B | $32B | – | $544M | $352M | $2.4B | – | $526M | $213M | $4.5B | $5.6B | $6.6B | $219M |
| 2013 | $16.4B | $2.6B | $33.5B | – | $478M | $311M | $2.3B | $433M | $537M | $191M | $3.7B | $3.6B | $7.4B | – |
| 2012 | $17.6B | $2B | $36.3B | – | $676M | −$161M | $2.3B | $2.4B | $548M | $154M | $3.9B | $1.7B | $6.6B | $7.5B |
| 2011 | $21.2B | $3.7B | $31.7B | – | $597M | $1.7B | $2.3B | $1.2B | $367M | $161M | $3.8B | $5.8B | $5.4B | $360M |
Sources: SEC, Wikidata
How to cite
Bristol Myers Squibb, Financials. Alion, Nov 21, 2026. https://alion.io/company/bms/financials
